Varying strategies among managed care organizations for PCSK9 inhibitors will shape the care of high-risk cardiovascular patients.
Matt Jarvis, PharmD
Advertisement
Articles by Matt Jarvis, PharmD
Advertisement
Latest Updated Articles
PCSK9 Inhibitors: Who are the Best Candidates for Therapy?Published: August 16th 2016 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
CDC Layoffs Raise Questions About the Future of Public Health Surveillance
2
From $200,000 in Student Loan Debt to Becoming a 7-Figure Pharmacist
3
Inhaled Insulin Demonstrates Comparable Safety, Lung Function, and Efficacy to Injectable Insulin in Type 1 Diabetes
4
FDA Approves Updated Indication for Upadacitinib in Patients With IBD
5
